ANDA 214523, held by Precision Dose Inc. Alendronate Sodium.
As of Nov 16, 2026, ANDA 214523 (Alendronate Sodium), held by Precision Dose Inc, was first approved by FDA on Sep 2, 2026, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 2, 2026 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Alendronate SodiumEQ 70MG BASE/75ML ยท solution;oral | Alendronate Sodium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters